El interés en corto de Petros Pharma da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Petros Pharma. Los datos de interés en corto se actualizan cada dos semanas.

Petros Pharma (NASDAQ:PTPI) Bolsa, Informe de interés en corto

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>TransDigm Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TDG, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for TransDigm Gr.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 26% bullish and 60%, bearish.</p>
<p>Out of all of the special options we uncovered, 12 are puts, for a total amount of $1,689,007, and 3 are calls, for a total amount of $122,970.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $765.0 and $1325.0 for TransDigm Gr, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for TransDigm Gr's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of TransDigm Gr's whale trades within a strike price range from $765.0 to $1325.0 in the last 30 days. </p>
<h3>TransDigm Gr Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731694605_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$31.3</td>
<td>$30.6</td>
<td>$31.3</td>
<td>$1305.00</td>
<td>$356.8K</td>
<td align="right">121</td>
<td align="right">114</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$54.2</td>
<td>$52.0</td>
<td>$53.5</td>
<td>$1250.00</td>
<td>$292.5K</td>
<td align="right">0</td>
<td align="right">83</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$30.7</td>
<td>$29.0</td>
<td>$29.0</td>
<td>$1200.00</td>
<td>$287.1K</td>
<td align="right">4</td>
<td align="right">205</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$26.8</td>
<td>$22.4</td>
<td>$26.0</td>
<td>$1200.00</td>
<td>$252.2K</td>
<td align="right">4</td>
<td align="right">103</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.0</td>
<td>$11.2</td>
<td>$17.0</td>
<td>$1265.00</td>
<td>$170.0K</td>
<td align="right">34</td>
<td align="right">102</td>
</tr>
</tbody>
</table>
</p>
<h3>About TransDigm Gr</h3>
<p>TransDigm manufactures and services a diverse set of specialized parts for commercial and military aircraft. The firm organizes itself in three segments: power and control, airframes, and a small non-aviation segment, which serves mostly off-road vehicles and mining equipment. It operates as an acquisitive holding company that focuses its portfolio on firms that make proprietary aerospace products with substantial aftermarket demand. TransDigm regularly employs financial leverage to amplify its operating results.</p>
<p>Having examined the options trading patterns of TransDigm Gr, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of TransDigm Gr</h3>
<ul>
<li>With a trading volume of 236,246, the price of TDG is up by 1.44%, reaching $1290.0.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for TransDigm Gr</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $1531.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on TransDigm Gr with a target price of $1500.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on TransDigm Gr, which currently sits at a price target of $1563. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest TransDigm Gr options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

TransDigm Gr Unusual Options Activity

<p><strong>Pfizer Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are lower on Thursday due to<a href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers"> news </a>that President-elect Donald Trump picked Robert F. Kennedy Jr. as his next secretary of the Department of Health and Human Services. This has some investors concerned because Kennedy was critical of certain vaccines and vaccinations.</p>
<p>Some believe the weakness in the stock may present a buying opportunity. This is why our team of expert traders and technical analysts has made it our <strong>Stock of the Day</strong>.</p>
<p>On Wall Street, many trading strategies and methods are based on the concept of reversion to the mean. If something goes too far one way, there is a good chance that it reverses and comes back the other way.</p>
<p>Most of the time, a stock stays in what is known as its trading range. But sometimes investors and traders can become emotional and aggressive. They can push the shares out of the range.</p>
<p>When this happens, there may be opportunities to profit. There is a good chance there will be a reversion back to the mean.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1024x529.png" alt="" class="wp-image-650959" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1536x794.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1.png 1583w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read Also:</strong> <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill">WHO Calls Vaccines &#8216;Absolutely Critical&#8217; As Trump&#8217;s Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill</a></p>
<p>If a stock is below its typical or average range, traders say that it is &#8220;oversold.&#8221; Some anticipate a reversal back to the average. This would mean a move higher.</p>
<p>So, they enter the market as buyers. This could put pressure on the stock and force the price higher. It could become a self-fulfilling prophecy.</p>
<p>The lower part of the chart is the Relative Strength Index (RSI) momentum indicator. When the blue line crosses below the horizontal red line, it indicates oversold conditions. As you can see, that is the case now. Pfizer is very oversold.</p>
<p>There is also another reason why the stock may reverse and head higher.</p>
<p>The shares have dropped to a price level that was support in April. Stocks tend to have support at levels that had been support before. Sometimes they can even rally off of support.</p>
<p>There are traders and investors who sold at the support level in April and regretted doing so when the price moved higher. Some decide to buy their shares back if they can at the same price they were sold.</p>
<p>So, now that the shares are back to their selling price, they are placing buy orders. This creates support.</p>
<p>The combination of being oversold and at support means there is a good chance Pfizer reverses and heads higher.</p>
<p><strong>Read Next:</strong><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants"> </a><br />    • <a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></p>
<p><em>Photo: Shutterstock</em></p>


Biotech

Health Care

Technicals

Trading Ideas

Stock Of The Day: Is Pfizer Set Up To Rally?

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Intuit</strong>.</p>
<p>Looking at options history for Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) we detected 14 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $224,213 and 9, calls, for a total amount of $436,947.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $560.0 to $730.0 for Intuit over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Intuit's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Intuit's significant trades, within a strike price range of $560.0 to $730.0, over the past month.</p>
<h3>Intuit Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731694599_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$5.1</td>
<td>$4.2</td>
<td>$4.8</td>
<td>$730.00</td>
<td>$120.0K</td>
<td align="right">5</td>
<td align="right">451</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$89.7</td>
<td>$87.2</td>
<td>$89.6</td>
<td>$720.00</td>
<td>$71.6K</td>
<td align="right">4</td>
<td align="right">10</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$94.7</td>
<td>$91.5</td>
<td>$94.7</td>
<td>$730.00</td>
<td>$66.2K</td>
<td align="right">9</td>
<td align="right">11</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$144.5</td>
<td>$140.9</td>
<td>$142.0</td>
<td>$560.00</td>
<td>$56.8K</td>
<td align="right">5</td>
<td align="right">2</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$81.7</td>
<td>$80.0</td>
<td>$80.42</td>
<td>$610.00</td>
<td>$56.2K</td>
<td align="right">80</td>
<td align="right">7</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuit</h3>
<p>Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.</p>
<p>Having examined the options trading patterns of Intuit, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Intuit</h3>
<ul>
<li>Currently trading with a volume of 650,880, the INTU's price is down by -2.25%, now at $685.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>Professional Analyst Ratings for Intuit</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $800.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Intuit, targeting a price of $800. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuit with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


INTU

What the Options Market Tells Us About Intuit

<p>Financial giants have made a conspicuous bullish move on Royal Caribbean Gr. Our analysis of options history for Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 27% of traders were bullish, while 27% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $238,532, and 8 were calls, valued at $709,157.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $240.0 for Royal Caribbean Gr, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Royal Caribbean Gr's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Royal Caribbean Gr's whale trades within a strike price range from $120.0 to $240.0 in the last 30 days. </p>
<h3>Royal Caribbean Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731694594_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$117.55</td>
<td>$116.0</td>
<td>$116.0</td>
<td>$120.00</td>
<td>$232.0K</td>
<td align="right">200</td>
<td align="right">20</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$26.15</td>
<td>$24.25</td>
<td>$25.2</td>
<td>$207.50</td>
<td>$136.0K</td>
<td align="right">185</td>
<td align="right">69</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$34.0</td>
<td>$31.9</td>
<td>$32.89</td>
<td>$200.00</td>
<td>$131.4K</td>
<td align="right">458</td>
<td align="right">40</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.2</td>
<td>$220.00</td>
<td>$126.0K</td>
<td align="right">633</td>
<td align="right">301</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.3</td>
<td>$4.15</td>
<td>$4.3</td>
<td>$220.00</td>
<td>$86.0K</td>
<td align="right">633</td>
<td align="right">538</td>
</tr>
</tbody>
</table>
</p>
<h3>About Royal Caribbean Gr</h3>
<p>Royal Caribbean is the world's second-largest cruise company, operating 68 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021.</p>
<h3>Present Market Standing of Royal Caribbean Gr</h3>
<ul>
<li>Currently trading with a volume of 665,083, the RCL's price is down by -0.86%, now at $231.0. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>Professional Analyst Ratings for Royal Caribbean Gr</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $251.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Royal Caribbean Gr, which currently sits at a price target of $240.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Royal Caribbean Gr, targeting a price of $257.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Royal Caribbean Gr, targeting a price of $243.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Royal Caribbean Gr with a target price of $245.<br />
&#x2A; An analyst from Tigress Financial has decided to maintain their Buy rating on Royal Caribbean Gr, which currently sits at a price target of $270. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Royal Caribbean Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


A Closer Look at Royal Caribbean Gr's Options Market Dynamics

<p>On Friday, <strong>Eyenovia, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company&#8217;s Optejet dispensing platform <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42004665/eyenovia-provides-update-on-phase-3-chaperone-study" rel="noreferrer noopener">pediatric progressive myopia</a>.</p>
<p>Progressive myopia is a type of nearsightedness that worsens over time due to the eyeball growing too long.</p>
<p>The company said that an independent Data Review Committee (DRC) reviewed the CHAPERONE data and found that the trial is not meeting its primary endpoint of a less than 0.5 diopter progression in visual acuity over three years.</p>
<p>The DRC reviewed the safety and efficacy data from 252 evaluable patients. The DRC found that the rate of myopia progression was not significantly different between the two active treatment arms (0.01% and 0.1% atropine ophthalmic metered spray) and placebo.</p>
<p>In the safety analysis, all dosages and placebo appeared well-tolerated, with a mild and infrequent adverse event profile. Full study data has not yet been released to Eyenovia.</p>
<p>&#8220;We plan to terminate the study, review the data more thoroughly, and evaluate the next steps,&#8221; stated Michael Rowe, Eyenovia&#8217;s CEO.</p>
<p>In light of the results of this review, the company is considering strategic options, which may include a business combination, reverse merger, asset sales or a combination of those alternatives.</p>
<p>William Blair has downgraded <a target="_blank" href="https://www.benzinga.com/quote/EYEN/analyst-ratings" rel="noreferrer noopener">Eyenovia to Market Perform</a>.</p>
<p>The analyst says,&#8221; While the approval of Mydcombi provided important validation of Eyenovia's Optejet device, and the subsequent approval of clobetasol propionate ophthalmic solution 0.05% added another promising product to the company's commercial portfolio, we believe the negative results from the CHAPERONE study and limited capital to invest in the launch of clobetasol or further pipeline programs limits near-term upside.&#8221;</p>
<p><strong>Price Action:</strong> EYEN stock is down 68.2% at $0.1083 at last check Friday.</p>
<p><em>Image via Unsplash</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/11/42014448/teledyne-controls-eadl-xs-certified-for-boeing-737ng-aircraft-enhancing-data-security" target="_blank" rel="noreferrer noopener">Teledyne Controls&#8217; eADL XS Certified For Boeing 737NG Aircraft, Enhancing Data Security</a></strong></li>
</ul>


Analyst Color

Equities

News

Downgrades

Analyst Ratings

Movers

General

EYEN

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

<p><strong>Avicanna Inc. </strong>(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTCQX">AVCNF</a>) announced its financial results Thursday for the third quarter, disclosing<strong> revenue of CA$6.27 million ($4.49 million), compared to CA$6.25 million </strong>in the same period last year. The Toronto-based cannabis company also reported improved consolidated gross margin to 57% from 46% for the same period in 2023.</p>
<p>"We are pleased to report the results of another quarter showing progressive improvements across our four business pillars," stated CEO <strong>Aras Azadian</strong>. "Our continuous optimization efforts contributed to improvements in our overall financial performance, consolidated gross margins, and balance sheet. We are now better positioned to turn our attention towards our international growth initiatives and take further steps towards advancing our long-term business model."</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41998220/agrifys-q3-revenue-drop-18-6m-loss-amid-new-leadership">Agrify&#8217;s Q3 Revenue Drop, $18.6M Loss Amid New Leadership</a></strong></p>
<p><em><strong>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</strong></em></p>
<h2 class="wp-block-heading"><strong>Q3 Financial Highlights</strong></h2>
<ul>
<li>Gross profit was CA$3.7 million compared to CA$2.9 million in the comparable quarter last year.</li>
</ul>
<ul>
<li>Adjusted EBITDA was a loss of CA$293,931 compared to adjusted EBITDA loss of $473,650 in the corresponding period last year.</li>
<li>Net loss amounted to CA$786,388 compared to net loss of CA$1.42 million in the third quarter of 2023.</li>
<li>Fully repaid outstanding principle balance of approximately CA$1.3 million owed under non-convertible debenture.</li>
</ul>
<h2 class="wp-block-heading"><strong>Recent Milestones</strong></h2>
<p>In August, the biopharmaceutical company&nbsp;announced &nbsp;the <a href="https://www.benzinga.com/markets/cannabis/24/08/40403052/avicannas-cbg-products-reach-19-countries-denmark-joins-global-expansion">successful export of its Aureus-branded cannabigerol (CBG) products to Denmark</a>. This marked the 19th international market for Aureus-branded products and the 22nd market overall for Avicanna&#8217;s product range. The export was facilitated through Avicanna's majority-owned subsidiary, Santa Marta Golden Hemp SAS.</p>
<p>The same month, Avicanna <a href="https://www.benzinga.com/markets/cannabis/24/08/40628172/avicanna-secures-nearly-2m-in-private-placement-deal-amid-us-patent-win-for-cannabinoid-topical-">closed a non-brokered private placement</a> offering of its 6,620,692 ‎‎units at $0.30 per unit for aggregate gross proceeds of $1,986,207.</p>
<p>This year also, the company confirmed that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 20230025693A1, covering the company&#8217;s deep penetrating topical cannabinoid composition and methods for <a href="https://www.benzinga.com/markets/cannabis/24/08/40585810/avicanna-secures-us-patent-for-topical-cannabinoid-technology-to-treat-pain-and-inflammation" target="_blank" rel="noreferrer noopener">treating musculoskeletal inflammation and pain.</a></p>
<h2 class="wp-block-heading"><strong>Price Action</strong></h2>
<p><strong>Avicanna shares closed Thursday's market session flat at 17 cents a share.</strong></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/24/11/41992549/cv-sciences-q3-revenue-stable-amid-new-launches-financing"><strong>CV Sciences Q3: Revenue Stable Amid New Launches, Financing</strong></a></li>
</ul>
<p><em>Photo: Courtesy of Avicanna </em></p>


Cannabis

Earnings

AVCNF

Avicanna Reduces Net Loss And Improves Gross Profit, Focusing On International Markets

<p>Money is one of the top reasons couples fight – and when one partner hasn't worked for over a decade, tensions only rise. This was the case for a woman who recently called into financial advisor <a href="https://www.benzinga.com/personal-finance/24/11/41883704/start-with-a-beater-car-says-dave-ramsey-when-youre-debt-free-and-paying-cash-for-your-dream-ride-youll-appreciate-the-sacrifice">Dave Ramsey's show</a>, seeking advice on what to do about her husband, who's been unemployed for 13 years. Despite his Ph.D. in pharmaceutical chemistry, he hasn't held a job since his layoff in 2011, leaving her as the sole breadwinner.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"><strong> </strong><strong>How do you compare</strong></a>?</strong></li>
<li><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"><strong> </strong><strong>The percentage may shock you</strong></a>.</strong></li>
<li><strong><a href="https://www.benzinga.com/money/cd-valet-growth"><strong>CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</strong></a></strong></li>
</ul>
<p>As she described how they'd moved across the country, sought counseling and even enlisted resume help, Ramsey listened closely before giving her some straight talk: "This has nothing to do with the mechanics of finding a job … He doesn't want to work."</p>
<p>The woman explained that her husband's layoff coincided with shifts in the pharmaceutical industry and the economic crash, which made finding a comparable job difficult. But, as she's rebuilt her career, she's increasingly felt that his job search has been less than active. Ramsey laid it out: "Behavior is a language. What's he been telling you for a decade? ‘I don't work.'"</p>
<p><strong>Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"><strong> </strong><strong>to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</strong></a></strong></p>
<p>Co-host Dr. John Delony added that people in similar situations often take <a href="https://www.benzinga.com/startups/24/11/41852620/theres-a-great-place-to-go-when-youre-broke-to-work-says-dave-ramsey-about-a-piece-of-advice-he-got">whatever work they can find</a> to support their families. Ramsey pointed out, "I know too many people with Ph.D.s who got laid off but went to work at the grocery store or Walmart in the interim."</p>
<p>The caller admitted she'd encouraged him to find any job just to return to the workforce. Still, the years kept passing. Ramsey's co-host sympathized, but his message was tough: "This is about getting up off your butt." He continued, stressing that the woman's husband must feel the consequences of his inaction. "Somebody's going to have to love him enough to knock him out of the ditch," Ramsey advised, "because he ain't climbing out."</p>
<p><strong>See Also: </strong><strong>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"><strong> </strong><strong>Here&#8217;s how you can earn passive income with just $100.</strong></a></strong></p>
<p>The situation became even trickier when she admitted she'd consulted a lawyer, only to find she might have to pay alimony if she left him. For this caller, Ramsey's advice boiled down to one central theme … love sometimes means <a href="https://www.benzinga.com/personal-finance/24/09/40838359/dave-ramsey-says-youre-wasting-5-000-a-year-if-you-spend-13-70-a-day-on-things-you-dont-need">helping someone face their reality</a>.</p>
<p>With the unemployment rate for Ph.D. holders aged 25 and over at just 1%, a 13-year gap in work is practically unheard of. According to Time, men without full-time jobs are 33% more likely to get divorced than those who are employed. So it's no wonder this caller is fed up with her husband's lack of ambition – her frustration is more than understandable.</p>
<p>Ramsey's advice cuts to the core. Without intervention, this <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">situation likely won't change</a> and the toll it takes on finances and marriage could grow harder to ignore.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"><strong> </strong><strong>here&#8217;s a breakdown on how on what&#8217;s behind this formula.</strong></a></strong></li>
<li><strong>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv"><strong>The percentage may shock you</strong></a>.</strong></li>
</ul>


Personal Finance

Woman Says Husband With A Ph.D. Hasn't Worked In 13 Years – Dave Ramsey Tells Her To 'Love Him Enough to Knock Him Out of the Ditch'

<p>Citigroup  analyst Alicia Yap   maintains Dada Nexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>) with a Neutral and lowers the price target from $2 to $1.9.</p>


Price Target

DADA

Citigroup Maintains Neutral on Dada Nexus, Lowers Price Target to $1.9

<p>Citigroup  analyst Alicia Yap   maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Buy and raises the price target from $108 to $115.</p>


NTES

Citigroup Maintains Buy on NetEase, Raises Price Target to $115

<p>Citigroup  analyst Alicia Yap   maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $52 to $51.</p>


Citigroup Maintains Buy on JD.com, Lowers Price Target to $51

<p>Alliance Global Partners  analyst Gaurav Mehta   downgrades Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) from Buy to Neutral and announces $2 price target.</p>


SACH

Alliance Global Partners Downgrades Sachem Cap to Neutral, Announces $2 Price Target

<p><a href="https://www.politico.com/news/2024/11/15/trump-transition-steven-cheung-communications-director-00189857">https://www.politico.com/news/2024/11/15/trump-transition-steven-cheung-communications-director-00189857</a></p>
<p>Steven Cheung, who served as Donald Trump's principal spokesperson on his 2024 campaign and also served on his 2020 and 2016 campaigns, is joining the White House as communications director, according to a person with direct knowledge of the matter.</p>
<p>Cheung has been a near constant presence at Trump's side and a key member of his tight-knit presidential campaign, run by Susie Wiles and Chris LaCivita.</p>


Macro Economic Events

Politics

Economics

'Trump To Tap Campaign Spokesperson Steven Cheung As Communications Director' - Politico

<p>Alliance Global Partners  analyst Jeff Grampp   maintains Drilling Tools Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTI#NASDAQ">DTI</a>) with a Buy and lowers the price target from $7.5 to $5.5.</p>


Alliance Global Partners Maintains Buy on Drilling Tools Intl, Lowers Price Target to $5.5

Econ #s

U.S. Baker Hughes Oil Rig Count -1 At 478; U.S. Baker Hughes NatGas Rig Count -1 At 101; U.S. Baker Hughes Total Rig Count 584 Vs 585 Prior

<p>Wedbush  analyst Andreas Argyrides   reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and maintains $181 price target.</p>


Reiteration

ASND

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $181 Price Target

<p>Across the recent three months, 14 analysts have shared their insights on Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.36, a high estimate of $27.00, and a low estimate of $19.00. Experiencing a 10.31% decline, the current average is now lower than the previous average price target of $24.93. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693679_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Couchbase is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Austin Dietz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Couchbase. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Couchbase compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Couchbase's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Couchbase's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BASE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Couchbase analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Couchbase: A Closer Look</h2>
<p>Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.</p>
<h3>A Deep Dive into Couchbase's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Couchbase displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>19.59%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Couchbase's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-38.56%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Couchbase's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-15.56%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Couchbase's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-8.32%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Couchbase's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BASE

Navigating 14 Analyst Ratings For Couchbase

<p>In the latest quarter, 11 analysts provided ratings for Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $335.91, with a high estimate of $380.00 and a low estimate of $271.00. Observing a 7.25% increase, the current average has risen from the previous average price target of $313.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693672_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Equifax by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$333.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$304.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$307.00</td>
<td>$277.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Equifax. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Equifax compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Equifax's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Equifax's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EFX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Equifax analyst ratings.</strong></a></p>
<h2>All You Need to Know About Equifax</h2>
<p>Along with Experian and TransUnion, Equifax is one of the leading credit bureaus in the United States. Equifax's credit reports provide credit histories on millions of consumers, and the firm's services are critical to lenders' credit decisions. In addition, over 40% of the firm's revenue comes from workforce solutions, which provides income verification and employer human resources services. Equifax generates just over 20% of its revenue from outside the United States.</p>
<h3>Unraveling the Financial Story of Equifax</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Equifax showcased positive performance, achieving a revenue growth rate of <strong>9.3%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Equifax's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.8%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.94%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Equifax's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.15%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.11</strong>, Equifax adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 11 Analyst Ratings For Equifax

<p>In the latest quarter, 15 analysts provided ratings for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $68.4, with a high estimate of $85.00 and a low estimate of $58.00. Witnessing a positive shift, the current average has risen by 4.16% from the previous average price target of $65.67.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693662_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of CVS Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CVS Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for CVS Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CVS Health's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CVS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CVS Health analyst ratings.</strong></a></p>
<h2>Get to Know CVS Health Better</h2>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<h3>CVS Health: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.31%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> CVS Health's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>0.09%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CVS Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.12%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.03%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.1</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For CVS Health's Future

BRK/B

DOCU

LDOS

REGN

CNBC Halftime Report Final Trades: Berkshire Hathaway Inc. - B Shares, Regeneron Pharmaceuticals, DocuSign, Leidos Holdings

<p>MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for MPLX, revealing an average target of $49.12, a high estimate of $55.00, and a low estimate of $43.00. Marking an increase of 2.63%, the current average surpasses the previous average price target of $47.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731693651_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of MPLX's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to MPLX. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MPLX compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of MPLX's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MPLX's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MPLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MPLX analyst ratings.</strong></a></p>
<h2>Discovering MPLX: A Closer Look</h2>
<p>MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.</p>
<h3>A Deep Dive into MPLX's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining MPLX's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>2.28%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> MPLX's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>37.14%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> MPLX's ROE excels beyond industry benchmarks, reaching <strong>7.52%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.68%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> MPLX's debt-to-equity ratio is below the industry average at <strong>1.66</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MPLX

8 Analysts Have This To Say About MPLX

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Petros Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/"><strong>PTPI</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Petros Pharmaceuticals reported earnings per share of -$1.69. This was below the analyst estimate for EPS of -$1.44.</li><li>The company reported revenue of $1.39 million.</li><li>This was 4.21% worse than the analyst estimate for revenue of $1.45 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/ptpi-stock-earnings-petros-pharmaceuticals-for-q1-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024

Analyst Naz Rahman from Maxim Group maintained a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and keeping the price target at $4.0...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Strategic Shift to OTC Market and Positive Regulatory Prospects

Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Petros Pharmaceuticals (PTPI – Research Report). The associated price target ...

Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!</p>



<p>Moving stocks this morning are clinical trail updates, an earnings report, acquisition news and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Neo-Concept</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/"><strong>NCI</strong></a>) stock is rocketing more than 60% alongside heavy pre-market trading.</li>



<li><strong>Sify Technologies Limited &ndash; Rights</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/"><strong>SIFYR</strong></a>) shares are soaring over 29% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">before their delisting next week</a>.</li>



<li><strong>Longeveron </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/"><strong>LGVN</strong></a>) stock is surging more than 28% <a href="https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-120-today/">with clinical trial news</a>.</li>



<li><strong>Fangdd Network</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/"><strong>DUO</strong></a>) shares are gaining over 24% with strong early morning trading.</li>



<li><strong>Nxu </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/"><strong>NXU</strong></a>) stock is increasing more than 17% on heavy early morning trading.</li>



<li><strong>Sequans Communications</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/"><strong>SQNS</strong></a>) shares are rising over 16% today.</li>



<li><strong>Broadcom </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/"><strong>AVGO</strong></a>) stock is heading 13% higher on <a href="https://www.barrons.com/articles/broadcom-stock-split-earnings-0c75392f">Q2 earnings and stock split plans</a>.</li>



<li><strong>Aethlon Medical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/"><strong>AEMD</strong></a>) shares are climbing more than 11% without any clear news today.</li>



<li><strong>CaliberCos </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/"><strong>CWD</strong></a>) stock is jumping over 11% this morning.</li>



<li><strong>Roma Green Finance</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/"><strong>ROMA</strong></a>) shares are up more than 10% </li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Assure </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/"><strong>IONM</strong></a>) stock is crashing over 52% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318390446&amp;type=PDF&amp;symbol=IONM&amp;cdn=e3ce016dbdad608e6e12f639f088590d&amp;companyName=Assure+Holdings+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-06-12">terminating a merger agreement</a>.</li>



<li><strong>DDC Enterprise</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ddc-stock-quote/"><strong>DDC</strong></a>) shares are plummeting more than 28% after <a href="https://www.marketwatch.com/story/ddc-enterprise-shares-surge-after-purchase-of-omsom-2ae3de86?mod=markets">rallying yesterday on an acquisition</a>.</li>



<li><strong>Cara Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cara-stock-quote/"><strong>CARA</strong></a>) stock is diving over 20% alongside <a href="https://www.nasdaq.com/press-release/cara-therapeutics-announces-outcome-part-kourage-1-study-evaluating-oral">clinical trial results</a>.</li>



<li><strong>Petros Pharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/"><strong>PTPI</strong></a>) shares are tumbling more than 18% on Thursday morning.</li>



<li><strong>PainReform </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/"><strong>PRFX</strong></a>) stock is taking an over 16% beating this morning.</li>



<li><strong>J.Jill</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/jill-stock-quote/"><strong>JILL</strong></a>) shares are falling more than 16% after <a href="https://www.nasdaq.com/press-release/jjill-announces-pricing-public-offering-common-stock-2024-06-12">pricing a public offering</a>.</li>



<li><strong>EpicQuest Education</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/eeiq-stock-quote/"><strong>EEIQ</strong></a>) stock is dropping over 16% this morning.</li>



<li><strong>Expion360 </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/"><strong>XPON</strong></a>) shares are decreasing more than 14% today.</li>



<li><strong>KWESST Micro Systems</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/"><strong>KWE</strong></a>) stock is declining over 12% as it <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">comes off a recent rally</a>.</li>



<li><strong>VS Media</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/"><strong>VSME</strong></a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Petros Pharmaceuticals (PTPI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahma...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic Advancements

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Petros Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/"><strong>PTPI</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Petros Pharmaceuticals reported earnings per share of -37 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $1.42 million.</li><li>This was 1.50% better than the analyst estimate for revenue of $1.40 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/ptpi-stock-earnings-petros-pharmaceuticals-for-q2-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) yesterday. The company's shares closed ye...

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and decreased the price target to $1...

Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals' OTC Stendra

The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). John Shulman and Greg Bradley, both members of the board of directors at Petros P...

Board Reshuffle at Petros Pharmaceuticals Following Resignations

An update from Petros Pharmaceuticals ( ($PTPI) ) is now available. Petros Pharmaceuticals has amended its employment agreement with President Fady...

Petros Pharmaceuticals Amends President's Employment Terms

AEMD

AVGO

CARA

EEIQ

IONM

JILL

LGVN

PRFX

PTPI

ROMA

SIFYR

SQNS

VSME

XPON

Contracts

Press Releases

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Events

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Comments

Petros Pharma

Interés en corto

Petros Pharma (NASDAQ:PTPI) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL